Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF | V.TLT.W

Theralase Technologies Inc is a clinical stage pharmaceutical company. It is dedicated to the research and development of light activated Photo Dynamic Compounds, their associated drug formulations and technology platforms intended to safely and effectively; treat various cancers, bacteria and viruses. The Cool Laser Technology division designs, develops, manufactures and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, primarily in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.

Recent & Breaking News (TSXV:TLT)

Theralase Releases Q322 Interim Financial Statements

GlobeNewswire 7 days ago

Theralase (TSXV:TLT) grants stock options

Brieanna McCutcheon  November 21, 2022

Theralase® Grants Stock Options

GlobeNewswire November 21, 2022

Theralase Technologies (TSXV:TLT) closes private placement

John Ballem  November 18, 2022

Theralase ® Closes Private Placement Equity Financing

GlobeNewswire November 17, 2022

Theralase (TSXV:TLT) commences C$2.5M follow-on private placement equity financing

Azuka Onwuka October 3, 2022

Theralase® Commences $CAN 2.5 M Follow-On Private Placement Equity Financing

GlobeNewswire October 3, 2022

Theralase® Announces Warrant Extension

GlobeNewswire September 29, 2022

Theralase (TSXV:TLT) closes $2.5M private placement

John Ballem  September 23, 2022

Theralase® Closes $2.5M Private Placement Equity Financing

GlobeNewswire September 22, 2022

Theralase Releases Q222 Interim Financial Statements

GlobeNewswire August 29, 2022

Theralase (TSXV:TLT) granted Brazilian patent

Trevor Abes  June 28, 2022

Theralase Expands Intellectual Property Portfolio

GlobeNewswire June 28, 2022

Theralase (TSXV:TLT) research - one of the most downloaded papers in Translational Biophotonics

Shoran Devi June 24, 2022

Theralase® Research - One of the Top 10 Most Downloaded Papers

GlobeNewswire June 24, 2022

Theralase (TSXV:TLT) announces publication of its Phase Ib NMIBC clinical study

John Ballem  June 21, 2022

Theralase® Phase Ib NMIBC Clinical Study Published

GlobeNewswire June 21, 2022

Theralase Releases Q122 Interim Financial Statements

GlobeNewswire May 30, 2022

Theralase Release FY2021 Audited Financial Statements

GlobeNewswire April 29, 2022

Theralase (TSXV:TLT) bladder cancer clinical study shows encouraging responses

Caroline Egan  April 5, 2022